Lab
Vikor Scientific, LLC
Vikor Scientific, LLC was paid $27.03M by Medicaid between Oct 2018 and Dec 2024, across 70 billing codes. Its largest line is 87798, Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism — 34% of everything it billed.
33Billing provider infoVIKOR SCIENTIFIC, LLC
CHARLESTON, SC 29403
CHARLESTON, SC 29403
33aNPI1174009245assigned 07/12/2018
33bProvider typeClinical Medical Laboratory
28Total paid$27.03M
24GClaims1,283,289
24DCodes billed70
24AFirst – last monthOct 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in South Carolina
Rank by total paid#2 of 39
Median peer was paid$403K
This provider vs. median67×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 7,367 | $131K | |
| 2019 | 46,316 | $1.08M | |
| 2020 | 217,629 | $4.40M | |
| 2021 | 327,829 | $4.92M | |
| 2022 | 386,604 | $6.32M | |
| 2023 | 188,264 | $5.82M | |
| 2024incomplete | 109,280 | $4.38M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 34% | 124,124 | 81,624 | $9.09M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 21% | 153,549 | 68,465 | $5.69M |
| 87481 | 6.9% | 61,606 | 48,496 | $1.88M | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 3.4% | 11,962 | 7,943 | $930K |
| 87653 | 2.9% | 87,962 | 65,806 | $796K | |
| 87529 | 2.8% | 40,105 | 32,176 | $760K | |
| 87641 | 2.7% | 76,905 | 59,706 | $732K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 2.7% | 88,239 | 39,520 | $725K |
| 87500 | 2.6% | 79,008 | 61,464 | $715K | |
| 87631 | 2.3% | 30,284 | 20,626 | $630K | |
| 81514 | 2.2% | 6,723 | 6,131 | $593K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1.9% | 42,508 | 34,567 | $505K |
58 more codes
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.5% | 37,683 | $419K |
| 87640 | 1.5% | 77,097 | $398K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1.1% | 37,737 | $310K |
| 87486 | 1.1% | 42,851 | $300K | |
| 87541 | 1.0% | 41,591 | $279K | |
| 87581 | 1.0% | 41,588 | $276K | |
| 87625 | <1% | 28,587 | $261K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 29,260 | $258K |
| 87563 | <1% | 29,519 | $253K | |
| 87511 | <1% | 34,436 | $242K | |
| 87493 | <1% | 9,852 | $133K | |
| 87556 | <1% | 10,522 | $130K | |
| 87561 | <1% | 21,704 | $120K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 7,211 | $98K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 4,140 | $92K |
| 87506 | <1% | 2,006 | $75K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 5,674 | $64K |
| 87505 | <1% | 895 | $31K | |
| 87496 | <1% | 2,102 | $26K | |
| 87498 | <1% | 2,046 | $26K | |
| 87532 | <1% | 2,096 | $25K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,875 | $24K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,909 | $19K |
| 87471 | <1% | 2,666 | $15K | |
| 81201 | <1% | 16 | $14K | |
| 81317 | <1% | 17 | $14K | |
| 81292 | <1% | 16 | $12K | |
| 81298 | <1% | 16 | $12K | |
| 81321 | <1% | 16 | $11K | |
| 87507 | <1% | 118 | $10K | |
| 81404 | <1% | 26 | $8K | |
| 81295 | <1% | 16 | $7K | |
| 81405 | <1% | 18 | $6K | |
| 87634 | <1% | 1,163 | $4K | |
| 87503 | <1% | 1,189 | $4K | |
| 86769 | <1% | 155 | $4K | |
| 87799 | <1% | 257 | $2K | |
| 81226 | <1% | 138 | $962.70 | |
| 87551 | <1% | 37 | $926.36 | |
| 87533 | <1% | 39 | $699.79 | |
| 81328 | <1% | 114 | $628.05 | |
| 81225 | <1% | 154 | $622.06 | |
| 81231 | <1% | 117 | $608.06 | |
| 81230 | <1% | 117 | $409.53 | |
| 81241 | <1% | 49 | $335.97 | |
| 87512 | <1% | 14 | $323.92 | |
| 81291 | <1% | 117 | $246.98 | |
| 81240 | <1% | 49 | $222.90 | |
| 81319 | <1% | 17 | $172.41 | |
| 81227 | <1% | 119 | $139.85 | |
| 81401 | <1% | 19 | $109.60 | |
| 81203 | 0% | 16 | $0.00 | |
| 81162 | 0% | 16 | $0.00 | |
| 81323 | 0% | 16 | $0.00 | |
| 81300 | 0% | 16 | $0.00 | |
| 81355 | 0% | 48 | $0.00 | |
| 81297 | 0% | 16 | $0.00 | |
| 81294 | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHARRELSON, SHEA (CO-FOUNDER)
| Provider | Location | Paid |
|---|---|---|
| Silverpath, INC. | Blue Bell, PA | $1.03M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.